Please assess the completion status of the following clinical trial:

Trial Title: Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals able to understand and give written informed consent.~* Histologically or cytologically confirmed epithelial cancer of one of the following types:~  * Gastric adenocarcinoma (GC)~ * Esophageal cancer (EC)~ * Hepatocellular carcinoma (HCC)~ * Non-small-cell lung cancer (NSCLC)~ * Small-cell lung cancer (SCLC)~ * Epithelial ovarian cancer (EOC)~ * Cervical Cancer~ * Endometrial Cancer~ * Triple-negative breast cancer (TNBC)~ * Non-triple-negative breast cancer~ * Papillary thyroid cancer (excludes follicular, medullary, Hurthle cell, and anaplastic thyroid cancer)~ * Glioblastoma multiforme (GBM)~ * Hormone-refractory prostate cancer (HRPC)~ * Head and neck cancers- squamous cell (SCCHN)~ * Renal cell cancer (clear cell) (RCC)~ * Urothelial cancer~ * Stage IV (metastatic) disease (except for individuals with GBM).~* Refractory to or relapsed after at least one prior standard therapeutic regimen~* Adequate performance status (ECOG 0 or 1)~* Expected survival ≥ 6 months.~* Measurable disease by CT or MRI.~* At least 2 weeks beyond treatment (chemotherapy, investigational drugs including small molecular inhibitors, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities to Grade 1 or less (except alopecia).~* At least 2 weeks beyond high dose systemic corticosteroids (however, low dose corticosteroids \< 20 mg prednisone or equivalent daily are permitted).~* Adequate hematology without ongoing transfusional support (hemoglobin \> 9 g/dL, absolute neutrophil count (ANC) \> 1,500 per mm\^3, platelets \> 100,000 per mm\^3).~* Adequate renal and hepatic function (creatinine ≤ 2.0 x institutional upper limit of normal (IULN), bilirubin ≤ 1.5 IULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x IULN or 5 x IULN if know liver metastases).~* Otherwise, all toxicity at study entry ≤ Grade 1.~Exclusion Criteria:~* Women who are pregnant or lactating.~* Women of childbearing potential and fertile men unwilling to use effective contraception during study until conclusion of 12-week post-treatment evaluation period.~* Individuals with Gilbert's disease.~* Individuals with brain metastases can be enrolled only if treated, non-progressive brain metastases and off high-dose steroids (\> 20 mg prednisone or equivalent) for at least 4 weeks.~* Presence of bulky disease (defined as any single mass \> 7 cm in its greatest dimension). Individuals with a mass over 7 cm, but otherwise eligible, may be considered for enrollment after discussion and approval with the medical monitor.~* Individuals with active ≥ grade 2 anorexia, nausea or vomiting, and/or signs of intestinal obstruction.~* Individuals with non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while individuals with other prior malignancies must have had at least a 3-year disease-free interval.~* Individuals known to be HIV positive, hepatitis B positive, or hepatitis C positive.~* Known history of unstable angina, MI, or CHF present within 6 months or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy.~* Known history of clinically significant active COPD, or other moderate-to-severe chronic respiratory illness present within 6 months.~* Prior history of clinically significant bleeding, intestinal obstruction, or GI perforation within 6 months of initiation of study treatment.~* Infection requiring intravenous antibiotic use within 1 week.~* History of an anaphylactic reaction to irinotecan or ≥ Grade 3 GI toxicity to prior irinotecan,~* Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sacituzumab Govitecan-hziy (SG) 8 mg/kg (Type: EXPERIMENTAL): Participants will receive sacituzumab govitecan-hziy (SG) 8 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
- SG 10 mg/kg (Type: EXPERIMENTAL): Participants will receive SG 10 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
- SG 12 mg/kg (Type: EXPERIMENTAL): Participants will receive SG 12 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
- SG 18 mg/kg (Type: EXPERIMENTAL): Participants will receive SG 18 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete